F Mec Intl. Fin. (539552)
Fast GrowerScore breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹103.9 |
| Market Cap | ₹92.39 Cr |
| P/E Ratio | 51.34 |
| ROCE | 14.92% |
| ROE | 13.13% |
| Dividend Yield | 0% |
| Profit Growth | 65.91% |
| Debt/Equity | — |
| Sales Growth | 45.45% |
| 52-Week Range | ₹11.37 — ₹103.9 |
| Sector | Finance |
| Book Value | ₹20.9 |
Strengths
- Strong recent growth: sales up 45.45% and profit up 65.91%, with PEG at 0.92
- Respectable return ratios: ROE of 13.13% and ROCE of 14.92%
- Piotroski F-Score of 7/9 indicates improving financial health
- Small absolute base gives potential for continued rapid growth if execution holds
Concerns
- Tiny scale: latest quarter sales are just ₹3 Cr and net profit ₹1 Cr, making percentage growth less meaningful
- Rich valuation: P/E of 51.34 and P/B of 4.97 leave little margin of safety
- No dividend and promoter holding undisclosed; FairStock Score shows insufficient data
- 52-week range of ₹11.37 to ₹103.90 shows the stock has already re-rated sharply, raising expectations
AI Analysis
I approach this stock as a businessman first, not a trader. F Mec Intl. Fin. is a micro-cap NBFC with a market cap of just ₹92 crore. At ₹103.90, it trades at 51.34 times earnings and 4.97 times book value. That is not a Graham bargain. But high multiples can be justified if growth is exceptional and durable. The recent figures are striking: sales grew 45.45% and profit grew 65.91%, giving a PEG of 0.92. On the surface, this looks like a fast grower. However, I cannot ignore the tiny base: latest quarter sales were only ₹3 crore and net profit ₹1 crore. It is far easier to post big percentage growth when you are starting from almost nothing. ROE of 13.13% and ROCE of 14.92% are respectable, but not exceptional for a lender. There is no dividend, promoter holding is not disclosed, and the FairStock Score is unavailable, so I am flying with incomplete instruments. The Piotroski score of 7/9 is a positive indicator of financial health, but it does not tell me enough about asset quality or capital adequacy. The 52-week range of ₹11.37 to ₹103.90 tells me the market has already discovered this stock and re-rated it dramatically. The core question is whether this business can be worth more in ten years. A company earning ₹1 crore in a quarter must prove it can scale while keeping risks controlled. I would not buy at this price without evidence of a durable moat and trustworthy management. Growth is attractive, but value comes from buying good businesses at fair prices. At five times book and fifty-one times earnings, the price is full of hope. I prefer a margin of safety.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer